A Safety, Tolerability, and Efficacy Study of IBI314 in Patients With Mild to Moderate COVID-19

Summary

This is a Phase 1/2 study evaluating the safety, tolerability and efficacy of IBI314.

Timeline

Start

2021-12-31

Primary completion

2022-08-31

Completion

2023-01-31

Outcome

Outcome not reported

Stopped (Business): “Due to the company's development strategy adjustment, Innovant Biologics decided not to continue this study after consultation with investigators.”

Drugs

Indications